Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $15,053.58 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 24,678 shares of the stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $0.61, for a total value of $15,053.58. Following the transaction, the director directly owned 2,368,849 shares of the company’s stock, valued at approximately $1,444,997.89. The trade was a 1.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total value of $33,618.60.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total transaction of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total transaction of $15,476.44.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total transaction of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $22,448.16.

Werewolf Therapeutics Trading Down 4.8%

NASDAQ HOWL traded down $0.03 during trading hours on Monday, hitting $0.57. 1,049,698 shares of the company were exchanged, compared to its average volume of 414,643. The stock has a 50-day moving average price of $0.89 and a 200 day moving average price of $1.25. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 52 week low of $0.56 and a 52 week high of $2.38. The stock has a market cap of $27.89 million, a PE ratio of -0.35 and a beta of 0.77.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOWL has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Wedbush cut shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target for the company. in a research note on Friday, December 19th. Zacks Research downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Citigroup downgraded shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Finally, Citizens Jmp lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC bought a new position in Werewolf Therapeutics in the 1st quarter worth about $79,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics during the second quarter valued at approximately $92,000. Quadrature Capital Ltd purchased a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $28,000. Marshall Wace LLP bought a new position in Werewolf Therapeutics in the second quarter worth approximately $113,000. Finally, Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics during the 2nd quarter worth $48,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.